Nephrogenic systemic fibrosis: Possible association with a predisposing infection

American Journal of Roentgenology

Volumn 190, Issue 4, 2008, Pages 1069-1075

  Golding, Lauren Parks ^a,b   Provenzale, James M ^c  

^a Moses H Cone Hospital   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Connective tissue disorders; Contrast media; Dialysis; Infections; MRI; Nephrogenic systemic fibrosis; Renal failure

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY FIBROSIS; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; BIOPSY; CHEMICALLY INDUCED DISORDER; FEMALE; FIBROSIS; MALE; PROSPECTIVE STUDY; RISK FACTOR; SKIN DISEASE;

AGED; BIOPSY; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM DTPA; HUMANS; INFECTION; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SKIN DISEASES;

EID: 42449129986     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.2884     Document Type: Article

References (21)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous disease in renal-dialysis patients. Lancet 2000; 356:1000-1001
2. Cowper SE. The International Center for Nephrogenic Fibrosing Dermopathy Research Website. www.icnfdr.org. Accessed July 12, 2007
3. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35:238-249
4. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108
5. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362
6. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003; 114:563-572
7. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-157
8. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927; 22:209-212
9. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 1998; 52:119-126
10. Mehta CR, Patel NR, Gray R. On computing an exact confidence interval for the common odds ratio in several 2 x 2 contingency tables. J Am Stat Assoc 1985; 80:969-973
11. Edsall LC, English JC III, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 2004; 31:247-253
12. Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? MAGMA 2007; 20:57-62
13. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56:27-30
14. Pilling D, Tucker NM, Gomer RH. Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukocyte Biol 2006; 79:1242-1251
15. Ortonne N, Lipsker D, Chantrel F, Boehm N, Grosshans E, Cribier B. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol 2004; 150:1050-1052
16. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003; 25:358
17. Pryor JG, Poggioli G, Galaria N, et al. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. J Am Acad Dermatol 2007; 57:105-111
18. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 2007; 188:586-592
19. Thomsen HS, ed. Contrast media: safety issues and ESUR guidelines. Berlin, Germany: Springer, 2006:47-52
20. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:21-26
21. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2002; 42:339-341